Owkin CEO Thomas Clozel (L) and CSO Gilles Wainrib
Following tie-up with Sanofi, transatlantic AI firm secures latest Big Pharma deal in nine-figure Bristol Myers pact
More than six months after securing a nine-figure deal with Sanofi for target discovery, a French AI research group has landed its next Big Pharma …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
